Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

mor masses is a major unmet need in a wide range of settings. It is our belief that, as a result, this technology has the potential to provide a broadly active new modality to substantially improve patient outcomes in a variety of hard-to-treat tumor types. "

Phase III Study Design

The Phase III study design agreed with the FDA follows directly from the design of the previous study. The Phase III study will also enroll previously untreated patients with locally advanced disease. The primary objective of the study will be to demonstrate a statistically significant increase in 2-year event free survival (i.e. relapse, progression, or death) for patients treated with chemoradiation together with OncoVEX (GM-CSF) as compared to patients treated with chemoradiation alone. The study will involve approximately 400 patients with approximately 200 in each arm.

Phase I/II Study Design and Results

In a Phase I/II study, OncoVEX (GM-CSF) was administered by direct injection, at three dose levels, into tumor containing lymph nodes in combination with standard first line chemo radiotherapy every three weeks for four cycles. All patients then went for surgery. Of the 17 patients enrolled, 16 had Stage IV N2 or N3 disease. OncoVEX (GM-CSF) was shown to be well tolerated with no significant side effects in addition to those associated with chemoradiation. With respect to efficacy, 93% of patients had a complete pathological response at surgery, with five patients achieving a complete response after only 2 or 3 virus doses. No patient to date has had a loco-regional recurrence in the neck at a median follow up of 30 months, and the disease specific survival rate is currently 82%.

Dr Robert Coffin, Founder and Chief Technology Officer, for BioVex, said:

"Loco-regional control is extremely important in head and neck cancer where loco regional progr
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... EXTON, Pa., March 2 Morphotek(R), Inc., a ... that it has commenced a,multi-centered Phase II study ... will evaluate MORAb-009, plus the chemotherapy drugs,pemetrexed and ... , The primary objective ...
... Calif., March 2 Pearl Therapeutics, a biopharmaceutical ... prevalent respiratory diseases, announced today the appointment of ... to attract a corporate leader with such an ... Ph.D., Venture Partner at 5AM Ventures and Executive ...
... in Managing Indoor and Outdoor AllergiesATLANTA and BRIDGEWATER, N.J., ... season quickly approaches, people living with nasal allergies should ... before they hit home. To help the nation,s estimated ... nasal allergy season, UCB and sanofi-aventis have enlisted a ...
Cached Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Sensor Market 2015-2019" report to their offering. ... major trend upcoming in this market is the increasing ... help in recording of patient data for quick and ...
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this ... technology, it is important to upgrade biometric solutions to ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... reliable indicators to predict that a person will develop type ... produced in the pancreas and is the hormone responsible for ... body, such as muscles. Insulin resistance is characterized by the ... a greater production of insulin by the pancreas. When the ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide provider of ... quarter of 2008. , Total ... $15.6 million for the third quarter of 2007. The decrease ... year ago was largely due,to lower revenues in the U.K. , ...
... ARLINGTON, Va., Nov. 18 Stanley, Inc.,(NYSE: ... professional,services to the U.S. federal government, today announced that ... International Corporation (NYSE: SAI ) awarded,a four-year, ... if,all three option years are exercised. With this award, ...
Cached Biology News:Researchers at IRB Barcelona produce more data on key genes in diabetes 2Researchers at IRB Barcelona produce more data on key genes in diabetes 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 2Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 3
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
...
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
Biology Products: